An update on clinical utility of rilpivirine in the management of HIV infection in treatment-naïve patients

References

• ChunTWCarruthLFinziDQuantification of latent tissue reservoirs and total body viral load in HIV-1 infectionNature19973871831889144289
   PubMed Web of Science ®Google Scholar
• RichmanDDMargolisDMDelaneyMGreeneWCHazudaDPomerantzRJThe challenge of finding a cure for HIV infectionScience20093231304130719265012
   PubMed Web of Science ®Google Scholar
• PomerantzRJHornDLTwenty years of therapy for HIV-1 infectionNat Med2003986787312835707
   PubMed Web of Science ®Google Scholar
• YoungJRickenbachMWeberRBody fat changes among antiretroviral-naïve patients on PI- and NNRTI-based HAART in the Swiss HIV cohort studyAntivir Ther200510738115751765
   PubMed Web of Science ®Google Scholar
• YoungJWeberRRickenbachMLipid profiles for antiretroviral-naïve patients starting PI- and NNRTI-based therapy in the Swiss HIV cohort studyAntivir Ther20051058559116152752
   PubMed Web of Science ®Google Scholar
• GardnerEMBurmanWJMaraviMEDavidsonAJDurability of adherence to antiretroviral therapy on initial and subsequent regimensAIDS Patient Care STDS20062062863616987049
   PubMed Web of Science ®Google Scholar
• ChesneyMAFactors affecting adherence to antiretroviral therapyClin Infect Dis200030Suppl 2S171S17610860902
   PubMed Web of Science ®Google Scholar
• StoneVEHoganJWSchumanPAntiretroviral regimen complexity, self-reported adherence, and HIV patients’ understanding of their regimens: survey of women in the her studyJ Acquir Immune Defic Syndr20012812413111588505
   PubMed Web of Science ®Google Scholar
• ThompsonMAAbergJAHoyJFAntiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panelJAMA201230838740222820792
   PubMed Web of Science ®Google Scholar
• Panel on Antiretroviral Guidelines for Adults and AdolescentsGuidelines for the Use of Antiretroviral Agents in HIV-1-Infected Adults and AdolescentsDepartment of Health and Human ServicesRockville, MD Available from: http://aidsinfo.nih.gov/contentfiles/lvguidelines/adultandadolescentgl.pdfAccessed March 1, 2013
   Google Scholar
• van LethFPhanuphakPRuxrungthamKComparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN StudyLancet20043631253126315094269
   PubMed Web of Science ®Google Scholar
• CliffordDBEvansSYangYImpact of efavirenz on neuropsychological performance and symptoms in HIV-infected individualsAnn Intern Med200514371472116287792
   PubMed Web of Science ®Google Scholar
• FundaroCGenoveseORendeliCTamburriniESalvaggioEMyelomeningocele in a child with intrauterine exposure to efavirenzAIDS20021629930011807320
   PubMed Web of Science ®Google Scholar
• MolinaJMAndrade-VillanuevaJEchevarriaJOnce-daily atazanavir/ritonavir compared with twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naïve HIV-1-infected patients: 96-week efficacy and safety results of the CASTLE studyJ Acquir Immune Defic Syndr20105332333220032785
   PubMed Web of Science ®Google Scholar
• MillsAMNelsonMJayaweeraDOnce-daily darunavir/ritonavir vs lopinavir/ritonavir in treatment-naïve, HIV-1-infected patients: 96-week analysisAIDS2009231679168819487905
   PubMed Web of Science ®Google Scholar
• EronJJJrRockstrohJKReynesJRaltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trialLancet Infect Dis20111190791521933752
   PubMed Web of Science ®Google Scholar
• MadrugaJVCahnPGrinsztejnBEfficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trialLancet2007370293817617270
   PubMed Web of Science ®Google Scholar
• KatlamaCClotetBMillsAEfficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trialsAntivir Ther2010151045105221041921
   PubMed Web of Science ®Google Scholar
• GirardPMCampbellTGrinsztejnBPooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interestHIV Med201213742743522413938
   PubMed Web of Science ®Google Scholar
• JanssenPALewiPJArnoldEIn search of a novel anti-HIV drug: multidisciplinary coordination in the discovery of 4-[[4-[[4-[(1E)-2-cyanoethenyl]-2,6-dimethylphenyl]amino]-2-pyrimidinyl]amino]benzonitrile (R278474, rilpivirine)J Med Chem2005481901190915771434
   PubMed Web of Science ®Google Scholar
• DasKBaumanJDClarkADJrHigh-resolution structures of HIV-1 reverse transcriptase/TMC278 complexes: strategic flexibility explains potency against resistance mutationsProc Natl Acad Sci U S A20081051466147118230722
   PubMed Web of Science ®Google Scholar
• LansdonEBBrendzaKMHungMCrystal structures of HIV-1 reverse transcriptase with etravirine (TMC125) and rilpivirine (TMC278): implications for drug designJ Med Chem2010534295429920438081
   PubMed Web of Science ®Google Scholar
• GoebelFYakovlevAPozniakALShort-term antiviral activity of TMC278–a novel NNRTI–in treatment-naïve HIV-1-infected subjectsAIDS2006201721172616931936
   PubMed Web of Science ®Google Scholar
• WilkinAPozniakALMorales-RamirezJLong-term efficacy, safety, and tolerability of rilpivirine (RPV, TMC278) in HIV type 1-infected antiretroviral-naïve patients: week 192 results from a phase IIb randomized trialAIDS Res Hum Retroviruses20122843744621902621
   PubMed Web of Science ®Google Scholar
• PozniakALMorales-RamirezJKatabiraEEfficacy and safety of TMC278 in antiretroviral-naïve HIV-1 patients: week 96 results of a phase IIb randomized trialAIDS201024556519926964
   PubMed Web of Science ®Google Scholar
• MolinaJMCahnPGrinsztejnBRilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naïve adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trialLancet201137823824621763936
   PubMed Web of Science ®Google Scholar
• CohenCJAndrade-VillanuevaJClotetBRilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naïve adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trialLancet201137822923721763935
   PubMed Web of Science ®Google Scholar
• CohenCJMolinaJMCahnPEfficacy and safety of rilpivirine (TMC278) versus efavirenz at 48 weeks in treatment-naïve HIV-1-infected patients: pooled results from the phase 3 double-blind randomized ECHO and THRIVE TrialsJ Acquir Immune Defic Syndr201260334222343174
   PubMed Web of Science ®Google Scholar
• CohenCJMolinaJMCassettiIWeek 96 efficacy and safety of rilpivirine in treatment-naïve, HIV-1 patients in two Phase III randomised trialsAIDS201327693995023211772
   PubMed Web of Science ®Google Scholar
• HuZKuritzkesDRInteraction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on ftness and RT activity of human immunodeficiency virus type 1J Virol201185113091131421849432
   PubMed Web of Science ®Google Scholar
• TambuyzerLVingerhoetsJAzijnHCharacterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studiesAIDS Res Hum Retroviruses2010261197120520854144
   PubMed Web of Science ®Google Scholar
• VingerhoetsJAzijnHTambuyzerLShort communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naïve patients and week 48 pooled DUET study dataAIDS Res Hum Retroviruses20102662162420507207
   PubMed Web of Science ®Google Scholar
• WheelerWHZiebellRAZabinaHPrevalence of transmitted drug resistance associated mutations and HIV-1 subtypes in new HIV-1 diagnoses, US-2006AIDS2010241203121220395786
   PubMed Web of Science ®Google Scholar
• WittkopLGünthardHFde WolfFEffect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort studyLancet Infect Dis20111136337121354861
   PubMed Web of Science ®Google Scholar
• VingerhoetsJRimskyLVan EygenVPreexisting mutations in the rilpivirine Phase III trials ECHO and THRIVE: prevalence and impact on virologic responseAntivir Ther201318225325622951490
   PubMed Web of Science ®Google Scholar
• HodderSArastehKDe WetJEffect of gender and race on the week 48 findings in treatment-naïve, HIV-1-infected patients enrolled in the randomized, phase III trials ECHO and THRIVEHIV Med20121340641522416849
   PubMed Web of Science ®Google Scholar
• NelsonMAmayaGClumeckNEfficacy and safety of rilpivirine in treatment-naïve, HIV-1-infected patients with hepatitis B virus/hepatitis C virus coinfection enrolled in the Phase III randomized, double-blind ECHO and THRIVE trialsJ Antimicrob Chemother2012672020202822532465
   PubMed Web of Science ®Google Scholar
• TaylorGPClaydenPDharJBritish HIV Association guidelines for the management of HIV infection in pregnant women 2012HIV Med201213Suppl 28715722830373
   PubMed Web of Science ®Google Scholar
• World Health OrganizationAntiretroviral Drugs for Treating Pregnant Women and Preventing HIV Infection in Infants: Guidelines on Care, Treatment and Support for Women Living with HIV/AIDS and their Children in Resource-Constrained SettingsGenevaWorld Health Organization2004 Available from: http://www.who.int/hiv/pub/mtct/guidelines/en/Accessed March 22, 2013
   Google Scholar
• PalellaFTebasPGazzardBSPIRIT study: switching to emtricitabine/rilpivirine/tenofovir df (FTC/RPV/TDF) single-tablet regimen (STR) from a ritonavir-boosted protease inhibitor and two nucleoside reverse transcriptase inhibitors (NRTIS) maintains HIV suppression and improves serum lipids19th International AIDS ConferenceJuly 22–27, 2012Washington DC Abstract TUAB0104
   Google Scholar
• MillsACohenCDeJesusESwitching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) single tablet regimen (STR) to emtricitabine/rilpivirine/tenofovir disoproxil fumarate (FTC/RPV/TDF) STR in virologically suppressed, HIV-1 infected subjects51st Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC)September 17–20, 2011Chicago, IL
   Google Scholar
• RimskyLVingerhoetsJVan EygenVGenotypic and phenotypic characterization of HIV-1 isolates obtained from patients on rilpivirine therapy experiencing virologic failure in the phase 3 ECHO and THRIVE studies: 48-week analysisJ Acquir Immune Defic Syndr201259394622067667
   PubMed Web of Science ®Google Scholar
• CohenCWohlDArribasJSTAR Study: single tablet regimen emtricitabine/rilpivirine/tenofovir DF is non-inferior to efavirenz/emtricitabine/tenofovir DF in ART-naïve adultsJ Int AIDS Soc201215Suppl 418221
   Google Scholar
• CrauwelsHvan HeeswijkRKestensDThe pharmacokinetic (PK) interaction between rifabutin and TMC278, an investigational non-nucleoside reverse transcriptase inhibitor (NNRTI)AIDS 2008 – XVII International AIDS ConferenceAugust 3–8, 2008Mexico City, MX Abstract TUPE0080
   Google Scholar
• ManosuthiWTantanathipPChimsuntornSTreatment outcomes of patients co-infected with HIV and tuberculosis who received a nevirapine-based antiretroviral regimen: a four-year prospective studyInt J Infect Dis201014e1013e101720880733
   PubMed Web of Science ®Google Scholar